KR100827558B1 - 카베르골린의 결정성 형태 ｉ의 제조방법 - Google Patents

카베르골린의 결정성 형태 ｉ의 제조방법 Download PDF

Info

Publication number
KR100827558B1
KR100827558B1 KR1020027012590A KR20027012590A KR100827558B1 KR 100827558 B1 KR100827558 B1 KR 100827558B1 KR 1020027012590 A KR1020027012590 A KR 1020027012590A KR 20027012590 A KR20027012590 A KR 20027012590A KR 100827558 B1 KR100827558 B1 KR 100827558B1
Authority
KR
South Korea
Prior art keywords
cabergoline
toluene
diethyl ether
ether mixture
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027012590A
Other languages
English (en)
Korean (ko)
Other versions
KR20020081587A (ko
Inventor
토마시앗틸리오
마제네스스테파니아
운가리마리오
라멜라줄리아노
팔란차잔프란코
Original Assignee
파마시아 이탈리아 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100827558(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 파마시아 이탈리아 에스.피.에이. filed Critical 파마시아 이탈리아 에스.피.에이.
Publication of KR20020081587A publication Critical patent/KR20020081587A/ko
Application granted granted Critical
Publication of KR100827558B1 publication Critical patent/KR100827558B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020027012590A 2000-03-24 2001-03-19 카베르골린의 결정성 형태 ｉ의 제조방법 Expired - Fee Related KR100827558B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
GB0007308.0 2000-03-24

Publications (2)

Publication Number Publication Date
KR20020081587A KR20020081587A (ko) 2002-10-28
KR100827558B1 true KR100827558B1 (ko) 2008-05-07

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027012590A Expired - Fee Related KR100827558B1 (ko) 2000-03-24 2001-03-19 카베르골린의 결정성 형태 ｉ의 제조방법

Country Status (31)

Country Link
US (2) US6727363B2 (https=)
EP (1) EP1272489B1 (https=)
JP (1) JP4184666B2 (https=)
KR (1) KR100827558B1 (https=)
CN (1) CN1188412C (https=)
AR (1) AR032449A1 (https=)
AT (1) ATE250601T1 (https=)
AU (2) AU780747B2 (https=)
BR (1) BR0109507A (https=)
CA (1) CA2402836A1 (https=)
CZ (1) CZ20023176A3 (https=)
DE (1) DE60100858T2 (https=)
DK (1) DK1272489T3 (https=)
EA (1) EA005928B1 (https=)
EE (1) EE05088B1 (https=)
ES (1) ES2208602T3 (https=)
GB (1) GB0007308D0 (https=)
HK (1) HK1052348B (https=)
HU (1) HUP0300591A3 (https=)
IL (2) IL150985A0 (https=)
MX (1) MXPA02009283A (https=)
MY (1) MY134189A (https=)
NO (1) NO20024321L (https=)
NZ (1) NZ521316A (https=)
PE (1) PE20011140A1 (https=)
PL (1) PL358253A1 (https=)
PT (1) PT1272489E (https=)
SI (1) SI1272489T1 (https=)
SK (1) SK13582002A3 (https=)
WO (1) WO2001070740A1 (https=)
ZA (1) ZA200206045B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
MXPA04008915A (es) * 2002-03-15 2005-06-20 Pharmacia Corp Proceso para la preparacion de la forma cristalina 1 de la cabergolina.
KR100605794B1 (ko) * 2002-03-15 2006-08-01 파마시아 코포레이션 카베르골린의 제1형 결정을 제조하는 방법
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
EP1620101A4 (en) * 2003-05-08 2008-07-09 Ivax Pharmaceuticals Sro POLYMORPHS OF CABERGOLIN
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
EP2185169A2 (en) * 2007-08-29 2010-05-19 Max Zeller Söhne AG Use of vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
WO1995005176A1 (en) 1993-08-18 1995-02-23 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
EP1075278A1 (en) 1998-01-13 2001-02-14 AstraZeneca UK Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY
SK13312000A3 (sk) 1998-03-27 2001-05-10 Pharmacia And Upjohn Company Použitie kabergolínu pri liečbe syndrómu nepokojných nôh
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas

Also Published As

Publication number Publication date
SK13582002A3 (sk) 2003-04-01
US6953854B2 (en) 2005-10-11
AU2005203071B2 (en) 2007-10-18
KR20020081587A (ko) 2002-10-28
MY134189A (en) 2007-11-30
EE200200545A (et) 2004-04-15
ATE250601T1 (de) 2003-10-15
PT1272489E (pt) 2004-02-27
DK1272489T3 (da) 2003-12-15
US6727363B2 (en) 2004-04-27
EA005928B1 (ru) 2005-08-25
NZ521316A (en) 2004-05-28
US20030149067A1 (en) 2003-08-07
SI1272489T1 (en) 2004-02-29
MXPA02009283A (es) 2003-03-12
PE20011140A1 (es) 2001-11-01
NO20024321D0 (no) 2002-09-10
EE05088B1 (et) 2008-10-15
ZA200206045B (en) 2003-07-29
CN1419554A (zh) 2003-05-21
IL150985A0 (en) 2003-02-12
GB0007308D0 (en) 2000-05-17
HK1052348B (zh) 2005-09-16
DE60100858T2 (de) 2004-07-29
CN1188412C (zh) 2005-02-09
AU780747B2 (en) 2005-04-14
AR032449A1 (es) 2003-11-12
IL150985A (en) 2007-03-08
PL358253A1 (en) 2004-08-09
JP4184666B2 (ja) 2008-11-19
JP2003528100A (ja) 2003-09-24
AU2005203071A1 (en) 2005-08-11
EP1272489A1 (en) 2003-01-08
CZ20023176A3 (cs) 2003-02-12
WO2001070740A1 (en) 2001-09-27
EP1272489B1 (en) 2003-09-24
HK1052348A1 (en) 2003-09-11
DE60100858D1 (de) 2003-10-30
US20040092744A1 (en) 2004-05-13
NO20024321L (no) 2002-09-10
HUP0300591A3 (en) 2009-01-28
HUP0300591A2 (hu) 2003-07-28
EA200201016A1 (ru) 2003-02-27
AU6211001A (en) 2001-10-03
ES2208602T3 (es) 2004-06-16
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
KR100827558B1 (ko) 카베르골린의 결정성 형태 ｉ의 제조방법
US20110112105A1 (en) Substituted heterocycle fused gamma-carbolines solid
US6800635B2 (en) Crystalline form II of cabergoline
US6680327B2 (en) Crystalline form VII of cabergoline
CA3059394C (en) Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
US20060281777A1 (en) Process for preparing crystalline form I of cabergoline

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110430

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110430

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000